Introduction

The Agency of Medicines and Medical Devices (AMDM) has released its statistical report on the pharmaceutical market of the Republic of Moldova for the first half (H1) of 2025. The latest figures reveal a market in transition, characterized by significant growth in monetary value alongside a slight contraction in sales volume, indicating a clear shift towards more innovative and higher-value medicines.
All data is based on producer prices in EURO, covering total imports and local production (RX and OTC) for the Republic of Moldova, excluding the Transnistrian region.

Key Market Dynamics: Value vs. Volume

The total value of the the Republic of Moldova pharmaceutical market in the first six months of 2025 reached €136.55 million.

The report highlights two opposing trends when comparing H1 2025 to the same period in 2024:

  • Value (EUR): The market saw a healthy growth of 8.27%.

  • Volume (Units): The market experienced a decrease of 2.88% in the number of units (boxes) sold.

This difference is explained by a combination of slight price increases and a notable "orientation towards more innovative and, implicitly, more expensive products". The market is also showing a stronger focus on treatments for chronic diseases.

Market Structure: Import vs. Domestic Production

The Republic of Moldova pharmaceutical market continues to be heavily dominated by imported products.

  • Imported Medicines: Account for 93% of the market value (€126.97 million) and 85.2% of the volume (41.08 million units).

  • Domestic Medicines: Represent 7% of the market value (€9.57 million) and 14.8% of the volume (7.16 million units).

A key positive trend for local industry is the continued growth of the domestic share in volume. At 14.8%, this is the "highest level in recent years," demonstrating a growing reliance on locally produced medicines.

Top Countries, Producers, and Products

Top 5 Import Countries (by Value): The import market is well-diversified, with 4 of the top 5 source countries being in the EU.

  1. Germany: €15.78 million (12%)

  2. Romania: €12.55 million (10%)

  3. Slovenia: €11.16 million (9%)

  4. Hungary: €9.80 million (8%)

  5. Turkiye: €9.15 million (7%)

Top 10 Foreign Producers (by Value): The top producers include a mix of 5 R&D companies, 3 European generics producers, and 2 companies with production primarily in Turkey.

  1. KRKA: €9.93 million

  2. Gedeon Richter: €7.83 million

  3. Berlin-Chemie: €7.25 million

  4. GlaxoSmithKline: €4.23 million

  5. World Medicine: €3.95 million

  6. AstraZeneca: €3.79 million

  7. Nobel: €3.45 million

  8. F. Homann-La Roche: €2.78 million

  9. Bayer: €2.76 million

  10. Sanofi: €2.70 million

Top 5 Local Producers (by Value):

  1. SC Balkan Pharmaceuticals SRL: €6.11 million

  2. Farmaprim SRL: €1.64 million

  3. SC Flumed-Farm SRL: €1.13 million

  4. ÎCS Eurofarmaco SA: €0.62 million

  5. ElaDum Pharma SRL: €0.08 million

Top 10 Imported DCIs (by Value): The list of top imported active ingredients highlights the focus on chronic conditions.

  1. Dapagliflozinum: €3.26 million

  2. Ibuprofenum: €2.41 million

  3. Rosuvastatinum: €2.00 million

  4. Rivaroxabanum: €1.86 million

  5. Pancreatinum: €1.41 million

  6. Ceftriaxonum: €1.39 million

  7. Medicamentum homeopathicum: €1.35 million

  8. Sulodexidum: €1.33 million

  9. Acidum acetylsalicylicum: €1.32 million

  10. Metforminum: €1.20 million

Distribution & Market Trends

The influence of the National Health Insurance Company (CNAM) is growing, impacting both imports and local production through its compensated medicines program.

The distribution sector is also seeing continued consolidation, a trend in line with the wider European market. Quality assurance remains a priority, with all licensed distributors in Moldova holding GDP (Good Distribution Practice) certificates or being in the process of certification.

Turn Market Data into Your Market Share

The H1 2025 report is clear: the Republic of Moldova pharmaceutical market is growing, specializing, and rewarding innovation. It is an ideal target for manufacturers seeking a stable, value-driven, and import-friendly European market.

However, data is only the beginning. Translating these opportunities into a successful business requires a partner on the ground.

This is where Lismedfarm steps in.

We are not just a service provider; we are your strategic partner for market entry and growth in the Republic of Moldova. This report provides the "what"—we provide the "how."

Lismedfarm can assist your company with a complete suite of solutions for market entry and distribution:

  • Registration and Maintenance: Comprehensive support for the initial registration and renewal of medicines, medical devices, and food supplements, including the management of variations and reauthorizations.

  • Specialized Services: Pharmacovigilance, manufacturer price registration, and authorized representation for medical devices.

  • Market Research and Distribution: Pharmaceutical market analysis, import, warehousing, and national distribution, including sub-distribution for pharmaceutical and parapharmaceutical products.

  • Promotion and Sales: Marketing, portfolio promotion, and representation in public health procurement.

Contact Us today to get a detailed analysis of your product portfolio's potential in the the Republic of Moldova market.

You can also consult our Manufacturer's Guide to Moldova's Pharma Market: 2025 Regulations & Statistics.